1. Home
  2. BEAM vs BATRA Comparison

BEAM vs BATRA Comparison

Compare BEAM & BATRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Beam Therapeutics Inc.

BEAM

Beam Therapeutics Inc.

HOLD

Current Price

$27.04

Market Cap

2.7B

Sector

Health Care

ML Signal

HOLD

Logo Atlanta Braves Holdings Inc. Series A

BATRA

Atlanta Braves Holdings Inc. Series A

HOLD

Current Price

$47.98

Market Cap

2.7B

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
BEAM
BATRA
Founded
2017
1991
Country
US
Employees
N/A
N/A
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Broadcasting
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
2.7B
2.7B
IPO Year
2019
N/A

Fundamental Metrics

Financial Performance
Metric
BEAM
BATRA
Price
$27.04
$47.98
Analyst Decision
Buy
Strong Buy
Analyst Count
14
3
Target Price
$46.00
$58.00
AVG Volume (30 Days)
1.5M
71.6K
Earning Date
04-01-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$24,000.00
N/A
Revenue This Year
N/A
$12.40
Revenue Next Year
$22.06
$6.78
P/E Ratio
N/A
N/A
Revenue Growth
33.33
N/A
52 Week Low
$13.53
$38.67
52 Week High
$36.44
$50.45

Technical Indicators

Market Signals
Indicator
BEAM
BATRA
Relative Strength Index (RSI) 47.29 75.02
Support Level $26.20 $43.04
Resistance Level $28.26 $48.59
Average True Range (ATR) 1.60 1.15
MACD -0.05 0.40
Stochastic Oscillator 62.60 81.57

Price Performance

Historical Comparison
BEAM
BATRA

About BEAM Beam Therapeutics Inc.

Beam Therapeutics Inc is a biotechnology company committed to creating a new class of precision genetic medicines based on its proprietary base editing technology, with a vision of providing lifelong cures to patients suffering from serious diseases. The company is focused on its programs in the hematology and genetic disease portfolios, which comprise different product candidates in its pipeline, such as BEAM-101, which is being developed to target Sickle Cell Disease, BEAM-302, a liver-targeting lipid nanoparticle, being developed to target Alpha-1 antitrypsin deficiency, and other drug candidates including BEAM-302, BEAM-103 & 104. The company views its operations and manages its business in one operating segment, operating exclusively in the United States.

About BATRA Atlanta Braves Holdings Inc. Series A

Atlanta Braves Holdings Inc is a holding company. It operates through its wholly-owned subsidiary, which is the owner and operator of the Atlanta Braves Major League Baseball Club and the mixed-use real estate development, The Battery Atlanta, and is the operator of the Atlanta Braves Major League Baseball Club's stadium, Truist Park. The company predominantly derives revenue related to the Braves baseball franchise and Truist Park from ticket sales, concessions, local broadcasting rights, advertising sponsorships, suites and premium seat fees, retail and licensing revenue, shared MLB revenue streams, including national broadcasting rights and licensing, and other sources. The company's reportable segments include: Baseball which generates key revenue, and Mixed-Use Development.

Share on Social Networks: